What are the treatments for CRPC after the ARPI has failed

Q: What are the treatments for CRPC after the ARPI has failed

When castration-resistant prostate cancer CRPC progresses despite androgen receptor pathway inhibitors ARPIs like abiraterone or enzalutamide, there are several evidence-based treatment approaches. Here's what current guidelines recommend: Chemotherapy - Docetaxel remains a cornerstone option. According to NCCN Guidelines for Prostate Cancer, docetaxel is recommended for CRPC patients who have progressed on prior ARPI therapy - Cabazitaxel a second-generation taxane is FDA-approved for patients

November 5, 2025Navis AI

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Treatment Options for CRPC After ARPI Failure

When castration-resistant prostate cancer (CRPC) progresses despite androgen receptor pathway inhibitors (ARPIs) like abiraterone or enzalutamide, there are several evidence-based treatment approaches. Here's what current guidelines recommend:

Standard Treatment Options

Chemotherapy

Docetaxel remains a cornerstone option. According to NCCN Guidelines for Prostate Cancer, docetaxel is recommended for CRPC patients who have progressed on prior ARPI therapy
Cabazitaxel (a second-generation taxane) is FDA-approved for patients who've already received docetaxel
These work by disrupting cancer cell division

Second-Line ARPIs

NCCN Guidelines recommend considering an alternative ARPI (switching from one to another) in selected patients, as some may still respond
Examples include switching to abiraterone if on enzalutamide, or vice versa

Immunotherapy

Pembrolizumab (Keytruda) received FDA approval for specific CRPC cases with microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR)
ASCO Guidelines note this is appropriate for eligible patients with these specific genetic markers

Emerging/Specialized Options

Radium-223: For CRPC with bone metastases (spreads to bones)
Lutetium-177 PSMA therapy: A newer nuclear medicine approach showing promise in clinical trials
Clinical trials: Often offer access to novel combinations or newer agents

Important Considerations

According to American Cancer Society recommendations, treatment choice depends on:

Where cancer has spread (metastatic vs. non-metastatic)
Prior treatments received
Your overall health and side effect tolerance
Genetic testing results (for immunotherapy eligibility)

Next Steps: Your oncologist should discuss which option best fits your specific situation, including genetic testing if not already done, and whether clinical trials might be appropriate for you.

Would you like me to explain any of these options in more detail?

This is general information.

Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.

Upload Records →Ask About Your Case →